文献速递结核与非结核分枝杆菌

自服每周一次异烟肼-利福喷丁对比每日利福平治疗成人潜伏性结核的完成率更高

Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该回顾性队列研究纳入美国结核门诊2016至2018年启动潜伏性结核治疗的成人,比较自服每周一次异烟肼-利福喷丁(3HP-SAT)与4个月每日利福平(4R)的完成率和不良事件。结果显示3HP-SAT在18-49岁和≥50岁人群中的完成率均高于4R,且≥50岁人群不良事件风险更低。

要点

  • 3HP-SAT在18-49岁和≥50岁人群中的治疗完成率均高于4R。
  • ≥50岁人群接受3HP-SAT的不良事件风险低于4R。
  • 18-49岁人群两种方案的不良事件风险无差异。

核心结论

  • 在≥50岁人群中,3HP-SAT与更高的潜伏性结核治疗完成率和更低的不良事件风险相关。
  • 扩大3HP-SAT作为潜伏性结核治疗选择可能增强美国的结核预防策略。

研究设计与样本

  • 中位年龄38岁,55%为女性,89%为非美国出生。
  • 通过药房配药评估治疗完成情况,并查阅病历了解未完成原因包括不良事件。
  • 使用χ2检验和对数二项多变量模型比较治疗完成率和不良事件。

主要发现

  • 18-49岁人群中,3HP-SAT治疗完成率为79%,4R为68%(aRR 1.17,95%CI 1.17-1.27,P<.0001)。
  • ≥50岁人群中,3HP-SAT治疗完成率为87%,4R为64%(aRR 1.35,95%CI 1.19-1.52,P<.0001)。

临床怎么用

  • 对于潜伏性结核感染成人,尤其是≥50岁者,可考虑将3HP-SAT作为治疗选项以提高完成率并降低不良事件风险。
  • 在临床决策中需结合患者年龄等因素选择潜伏性结核治疗方案。

局限性

  • 回顾性队列设计可能存在残余混杂。
  • 研究仅在美国单一结核门诊进行,外推性受限。
  • 治疗完成情况通过药房配药评估,可能不能完全反映实际服药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of latent tuberculosis (LTBI) is important for tuberculosis (TB) prevention, and short course rifamycin-based therapies are preferred. Once-weekly isoniazid-rifapentine by self-administered therapy (3HP-SAT) has never been compared with 4 months of daily rifampin (4R). METHODS: Retrospective cohort study of adults ≥18 years of age initiating LTBI treatment with either 3HP-SAT or 4R in a United States (US)-based TB clinic between 11 April 2016 and 31 December 2018. We evaluated treatment completion through pharmacy fills and reviewed charts for reasons of noncompletion, including adverse events (AEs). The χ 2 test and a log-binomial multivariable model were used to compare treatment completion and AEs. RESULTS: Five hundred sixty individuals (42%) initiated 3HP-SAT and 773 (58%) initiated 4R. Median age was 38, 55% were female, and 89% were born outside of the US. Among those aged 18-49 years, treatment completion with 3HP-SAT was 79% compared to 68% with 4R (adjusted risk ratio [aRR], 1.17 [95% CI, 1.17-1.27]; P < .0001). Among individuals aged ≥50 years, treatment completion with 3HP-SAT was 87% compared to 64% with 4R (aRR, 1.35 [95% CI, 1.19-1.52]; P < .0001). Compared to 4R, there was no difference in risk of AEs in the 18-49 age group (aRR, 0.93 [95% CI, .58-1.48]; P = .75). Reduced risk of AEs was noted among patients aged ≥50 years who received 3HP-SAT (aRR, 0.37 [95% CI, .16-.85]; P = .02). CONCLUSIONS: 3HP-SAT was associated with higher LTBI treatment completion and lower rates of AEs compared to 4R in individuals aged 50 and older. Expanding 3HP-SAT as an option for patients with LTBI may enhance TB prevention strategies in the US.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Haas MK, Aiona K, Erlandson KM, et al. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis. Clin Infect Dis. 2021. PMID: 32915203. doi:10.1093/cid/ciaa1364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。